Idarubicin

• CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics Recruiting
  2022-500295-60-00 Phase II 1 country Centre Hospitalier Universitaire De Nice
• TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE/TAE for patients with inte… Ended
  2024-513882-38-00 Phase II/III 1 country The Clatterbridge Cancer Centre NHS Foundation Trust
• A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NP… Ended
  2023-506582-58-00 Phase I (Other) 4 countries Janssen - Cilag International
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended
  2023-503640-14-00 Phase III 17 countries Amgen Inc.
• A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy, and pharmacokinetics in newly diagnosed pediatr… Ended
  2023-509834-20-00 Phase II 6 countries Novartis Pharma AG
• Study to determine safety, efficacy and tolerability of Venetoclax in combination with Fludarabine, Citarabine and Idarubicin to achieve "th… Ended
  2023-510517-26-00 Phase I/II 1 country Fondazione Gimema Franco Mandelli Onlus

Showing 1–6 of 6 trials